I think there’s a difference in the countries you point out.. the UK is going to move at about the pace of the FDA. It’s a smart move to go in That direction and potentially get an EAM to start. The Philippines is part of a global distribution plan which is assuming approval for HIV and/or Covid. A company who believes in their product and has indications their drug will get approved needs to do just that. If you can’t show distribution capabilities to governments they aren’t going to waste time on your drug and it’s not just Covid but hopefully HIV approval in 2021. So some of the frustration is possibly related to the speed of approvals being perceived as slow . 16 years in bio Pharma tells me that the reviews from regulatory bodies is actually moving pretty quickly.